THE UNIVERSITY OF BRITISH COLUMBIA
The Respiratory Evaluation Sciences Program (RESP) is a comprehensive epidemiology, health outcomes, and health economics program focused on chronic respiratory diseases (namely asthma and chronic obstructive pulmonary disease [COPD]).
We are hosted within Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, UBC. Our group has diverse expertise in using clinical data, real-world 'big' data, and computer simulations (disease modeling) techniques to evaluate the real-world effectiveness of health technologies and their 'value for money' potential. Our research has continuously been supported through multiple grants from CIHR and other agencies.
See more of our research by following categories:
Development and validation of the Evaluation Platform In COPD (EPIC): a population-based outcomes model of COPD for Canada
Med Decis Making. 2019 Feb;39(2):152-16
Validation and Utility Testing of Clinical Prediction Models: Time to Change the Approach
JAMA. 2020 Jul 21;324(3):235-236
Testing Clinical Prediction Models—Reply
We agree with Drs Goldstein and Pencina about the necessity of adapting risk models to the clinical use case. We share their vision that a cloud-based platform does not have to be centralized; each practitioner will set up their own environment for the mo...
RESP is hosted within Collaboration for Outcomes Research and Evaluation within UBC Faculty of Pharmaceutical Sciences. Our partners include UBC Division of Respiratory Medicine, and Centre for Clinical Epidemiology and Evaluation.
Our research has been funded by peer-reviewed grants from multiple institutions, including: